ST. LOUIS, May 6, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced several firsts for its eleventh appearance at the annual Heart Rhythm Society (HRS) Scientific Sessions, to be held May 7-10, 2014 in San Francisco, CA. With a central theme of "Efficiency Established; Outcomes Proven; Safety Undoubted," the Company will share new clinical evidence around efficiencies achieved through its Epoch™ Solution, showcase a seminal feature of its latest generation user interface and, for the first time, present the value of its Vdrive™ Robotic Navigation System to a U.S. audience.
"The electrophysiology (EP) community has long recognized Stereotaxis as world-class in safety and efficacy," said William C. Mills, Stereotaxis Chief Executive Officer. "Through an internal study, we now have evidence of significant improvement in procedure efficiency (as measured by achievable total procedure time and ablation time) and an accelerated learning curve using the Niobe® ES Magnetic Navigation System. Until now, the claim that a proficient Niobe user can often perform faster ablation procedures compared to alternative EP treatments has been largely anecdotal. This information provides a baseline for substantiation of improved efficiency as we continue to deliver advances in robotic EP ablation."
Among the innovations Stereotaxis is launching at HRS is a key feature of the Company's enhanced user interface for the Epoch platform. As its name indicates, Ablation History provides a history of the catheter's power output and duration of energy application at each location during the ablation through an intuitive graphical display. With this feature, physicians can retrace their ablation-related activity and potentially identify gaps in lesion lines on a real-time basis. The Company believes this additional capability will assist physicians in visualizing the applied treatment, reducing the need for touch-up at the end of the procedure and minimizing unnecessary tissue injury, which should lead to improved procedure efficiency and outcomes. Physicians will have the opportunity to see the feature in a live simulation lab at the Stereotaxis booth.Ablation History is the latest capability offered through a platform that has been utilized in approximately 70,000 robotic EP procedures to date. More than 500 EP physicians worldwide currently rely on Stereotaxis technology, which includes the Niobe system, Vdrive system and accessory disposables, and the Odyssey® Information Management Solution. The Vdrive robotic navigation system is a relatively new offering in the U.S., receiving FDA clearance of its V-Sono™ ICE Catheter Manipulator in July 2013. Now installed in nine U.S. sites, the system has aided in more than 100 Niobe procedures. In addition, the V-Loop™ Variable Loop Catheter Manipulator has been submitted for FDA clearance. This year represents the first opportunity the Company will have to formally present the features and benefits of the Vdrive system to HRS participants. During a breakfast symposium held at the HRS Rhythm Theatre on May 8 at 6:30 a.m. and moderated by Stereotaxis Chief Medical Officer Dr. Gery Tomassoni, two renowned EP physicians and researchers, Dr. Hiroshi Nakagawa (University of Oklahoma Health Sciences Center) and Dr. Eugene Crystal (Sunnybrook Health Sciences Centre, Toronto), will speak to the unique clinical value and procedure efficiency achieved with Stereotaxis solutions.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts